

SCIENTIFIC PROGRAM

Monday, July 9

08:15 – 08:45 Registration

08:45 - 09:00 Welcome address by **Peter Boyle**, Director IARC, Lyon

Session 1: Etiology and Molecular Epidemiology

Chair: I. Chemin & M. Ozturk

09:00 – 09:30 **S. Franceschi**, IARC, France
Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma

09:30 – 10:00 **A. Hall**, London, UK
HCC epidemiology – unanswered questions and prevention

10:00 – 10:30 **C. Wild**, Leeds, UK
Aflatoxins and hepatocellular carcinoma risk in developing countries

10:30 – 11:00 *Coffee break*

11:00 – 11:30 **M. Kew**, Johannesburg, South Africa
Hepatocarcinogenesis in Black Africans: Two recent studies

Session 2: Mechanisms and Viruses

Chair: B. Sylla & C. Wild

11:30 – 12:00 **H. Blum**, Freiburg, Germany
Hepatocellular Carcinoma: Mechanisms and viruses

12:00 – 12:30 **H. Norder**, Solna, Sweden
Genetic diversity of HBV in hepatocarcinogenesis

12:30 – 13:00 **K. Koike**, Tokyo, Japan
The X gene is implicated in the carcinogenicity of hepatitis B virus

13:00 – 14:30 *Lunch break*

14:30 – 15:00 **M. Feitelson**, Philadelphia, USA
Natural Effectors of HBxAg in Hepatocarcinogenesis

15:00 – 15:30 **F. Zoulim / I. Chemin**, Lyon, France
Hepatitis B virus infections and hepatocarcinogenesis

Session 3: Molecular Carcinogenesis

Chair: P. Hainaut & L. Beretta

- 15:30 – 16:00 **M. Levrero**, Rome, Italy
The role of the p53/paralog TP73 encoded proteins in human hepatocellular carcinoma
- 16:00 – 16:30 *Coffee break*
- 16:30 – 17:00 **M. Ozturk**, Ankara, Turkey
Induction of senescence as a potential therapeutic strategy in hepatocellular carcinoma
- 17:00 – 17:30 **J. Zucman-Rossi**, Paris, France
The genetic diversity of hepatocellular carcinomas and the potential for new targeted therapies
- 17:30 – 18:00 **K. Hui**, Singapore, Singapore
Clinical interpretations and potential applications of expression profiles of human hepatocellular carcinoma

Attendees make their own dinner arrangements- See Helpdesk for tips on restaurants.

Tuesday, July 10

Session 4: Preclinical Models and Therapeutic Approaches

Chair: S. Ognjanovic & M. Feitelson

- 08.30 – 09.00 **D. Kerr**, Oxford, UK
New treatments for liver cancer
- 09:00 – 09:30 **J. Bruix**, Barcelona, Spain
Current treatment and future prospects
- 09:30 – 10:00 **N. Fausto**, Seattle, USA
Targeting the stroma in hepatocarcinogenesis and the development of pre-clinical models for HCC treatment
- 10:00 – 10:30 **J. Marrero**, Michigan, USA
Prognosis and staging of hepatocellular carcinoma
- 10:30 – 11:00 *Coffee break*
- 11:00 – 11:30 **K. Zatloukal**, Graz, Austria
Hepatocellular carcinoma: From human disease to validated animal models

11:30 – 12:00 **Ph. Merle / C. Trepo**, Lyon, France
Different innovative therapeutic approaches for HCC: High dose 3D conformal radiation therapy (CRT) and vectorisation of doxorubicin by nanoparticles (Transdrug)

Session 5: Biomarkers

Chair: A. Plymoth & M. Levrero

12:00 – 12:30 **L. Beretta**, Seattle, USA
Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery

12:30 – 13:00 **R. Walton**, Banjul, The Gambia
Primary prevention, early detection, pathogenesis, and treatment of liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.

13:00 – 15:00 *Lunch break*

13:00 – 15:00 **Round-table discussion:**
Opportunities for international collaborations
Place: Sasakawa A and B
Chair: P. Hainaut & P. Boffetta

15:00 – 15:30 **P. Hainaut**, IARC, France
The aflatoxin-induced TP53 mutation at codon 249: biomarker of exposure, detection, and target for therapy.

15:30 – 16:00 **F. He**, Beijing, China
Proteome analysis of HBV-associated hepatocellular carcinoma in China

16:00 – 16:30 *Coffee break*

16:30 – 17:00 **G. Bonn**, Innsbruck, Austria
New analytical solutions for proteomics in biomarker discovery

17:00 – 17:30 **J. Zhu**, Shanghai, China
Working towards the DNA methylation based staging and classification system of hepatocellular carcinoma

17:30 – 18:00 **S-Z. Yu**, Shanghai, China
The Three Environmental Risk factors for Hepatocellular Carcinoma in China

18:00 *End of meeting*